首页> 美国卫生研究院文献>BioImpacts : BI >Development and evaluation of exemestane-loaded lyotropic liquid crystalline gel formulations
【2h】

Development and evaluation of exemestane-loaded lyotropic liquid crystalline gel formulations

机译:装载依西美坦的溶致液致液晶凝胶制剂的开发和评估

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

>Introduction: The use of liquid crystalline (LC) gel formulations for drug delivery has considerably improved the current delivery methods in terms of bioavailability and efficacy. The purpose of this study was to develop and evaluate LC gel formulations to deliver the anti-cancer drug exemestane through transdermal route. >Methods: Two LC gel formulations were prepared by phase separation coacervation method using glyceryl monooleate (GMO), Tween 80 and Pluronic® F127 (F127). The formulations were characterized with regard to encapsulation efficiency (EE), vesicle size, Fourier transform infrared (FTIR) spectroscopy, surface morphology (using light and fluorescence microscopy), in vitro release, ex vivo permeation, in vitro effectiveness test on MDA-MB231 cancer cell lines and histopathological analysis. >Results: Results exhibited that the EE was 85%-92%, vesicle size was 119.9-466.2 nm while morphology showed spherical vesicles after hydration. An FTIR result also revealed that there was no significant shift in peaks corresponding to Exemestane and excipients. LC formulations release the drug from cellulose acetate and Strat-MTM membrane from 15%-88.95%, whereas ex vivo permeation ranges from 37.09-63%. The in vitro effectiveness study indicated that even at low exemestane concentrations (12.5 and 25 μg/mL) the formulations were able to induce cancer cell death, regardless of the surfactant used. Histopathological analysis thinning of the epidermis as the formulations penetrate into the intercellular regions of squamous cells. >Conclusion: The results conjectured that exemestane could be incorporated into LC gels for the transdermal delivery system and further preclinical studies such as pharmacokinetic and pharmacodynamic studies will be carried out with suitable animal models.
机译:>简介:使用液晶(LC)凝胶制剂进行药物输送,从生物利用度和功效方面来看,已经大大改善了当前的输送方法。这项研究的目的是开发和评估LC凝胶制剂,以通过透皮途径递送抗癌药物依西美坦。 >方法:通过相分离凝聚法,使用甘油单油酸酯(GMO),吐温80和F127(F127)制备了两种LC凝胶制剂。在包封效率(EE),囊泡大小,傅立叶变换红外(FTIR)光谱,表面形态(使用光和荧光显微镜),体外释放,离体渗透,在MDA-MB231上进行体外有效性测试方面对制剂进行了表征癌细胞系和组织病理学分析。 >结果:结果显示,水合后EE为85%-92%,囊泡大小为119.9-466.2 nm,形态显示为球形囊泡。 FTIR结果还表明,对应于依西美坦和赋形剂的峰没有明显变化。 LC配方从15%-88.95%的醋酸纤维素和Strat-MTM膜中释放药物,而离体渗透率为37.09-63%。体外有效性研究表明,即使在低的依西美坦浓度(12.5和25μg/ mL)下,无论使用何种表面活性剂,该制剂也能够诱导癌细胞死亡。当制剂渗入鳞状细胞的细胞间区域时,表皮的组织病理学分析变薄。 >结论:结果推测,依西美坦可用于透皮给药系统的LC凝胶中,并将在合适的动物模型中进行进一步的临床前研究,如药代动力学和药效学研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号